SURVYR

CRSP

CRSP
$51.47
+$2.46 (5.02%)Oct 27 close
US Equities CompareTechnicals
1M3M6M1Y2Y
-33%-21%-9%+3%+15%Oct 2025Oct 2026Apr 202652w high $65.7252w low $44.34
CRSPSPY
Wall St. Highest PT $83.39 (+62.0%) Wall St. Avg PT $68.35 (+32.8%)
$44$56$68$79$91POC $54Hi $83Avg $68
Underwater Drawdown %Max DD -32.5%Current -21.7%
0.0%-32.5%
Relative Strength vs SPY-35.2% vs SPYUnderperforming
+44%0%-44%
1W
+$1.59 (3.19%)
1M
−$2.76 (5.09%)
3M
+$3.92 (8.24%)
6M
−$0.59 (1.13%)
YTD
−$0.97 (1.85%)
1Y
−$14.25 (21.68%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street & Morningstar coverage
Wall Street consensusNo covering analysts on file for CRSP
Analyst price targetsNo target range on file
Morningstar star ratingNot rated
Checked Wall Street & Morningstar feeds · All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

52-week range$44.34 – $65.72

What they do

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA.

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for CRSP yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

CRSP earningsNext report in 12 days
Next report · quarter Sep 2026
Mon Nov 9, 2026Time not confirmed
EPS consensus-$1.06
Revenue consensus–
Last 4 quarters · EPS vs estimate
Aug 3, 2026-$0.94est -$1.18+20.6%Above estimates
May 4, 2026-$1.28est -$1.23−3.7%Below estimates
Feb 12, 2026-$1.37est -$1.23−11.7%Below estimates
Nov 10, 2025-$1.17est -$1.29+9.2%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · refreshed 2026-10-26 18:45:43 ET
24-1125-0225-0525-0825-1126-0226-0526-08-1.580.00
EstimateActual (beat)Actual (miss)

News & catalysts

More news
Where Will CRISPR Therapeutics Stock Be in 2030?
Motley Fool · Oct 18
Insider trades
Kulkarni Samarth
Director, Chief Executive Officer · 2026-10-19
Sell
$2.4M
Kulkarni Samarth
Director, Chief Executive Officer · 2026-10-14
Sell
$201.9K
Kasinger James R.
General Counsel and Secretary · 2026-10-14
Sell
$51.2K
George Simeon
Director · 2026-10-14
Sell
$720.4K
Kasinger James R.
General Counsel and Secretary · 2026-10-06
Sell
$119.5K
Kasinger James R.
General Counsel and Secretary · 2026-09-22
Sell
$626.5K
Behbahani Ali
Director · 2026-09-17
Sell
$780.9K
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–

Stats refreshed 2026-10-26 18:45:43 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026